Nebulized AER101 in Pre-op NSCLC

Starting soon · Early Phase 1

Conditions studied: Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II

In brief

The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors. Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.

Key facts

Study ID

NCT07631299

Run by

University of Oklahoma

People needed

5

Starts

2026-06-01

Expected to finish

2027-06-01

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Agree to sign consent and follow study requirements
• Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma
• Primary patients prior to resection
• Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to)
• Baseline PET/CT imaging performed at Stephenson Cancer Center available and performed within previous 30 days

You may not qualify if…

• Recurrent tumor(s)
• Nodal or metastatic tumor (multiple lung tumors are acceptable)
• Pregnant patients
• Patients unable to provide informed consent
• Prisoners

Where it is running

• OU Medical Center Hospital — Oklahoma City, Oklahoma, United States
• Stephenson Cancer Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.